TCEAL3 Inhibitors

TCEAL3 Inhibitors target various aspects of the transcription process and RNA processing, which could influence the function of TCEAL3. α-Amanitin and DRB directly inhibit RNA polymerase II, a key enzyme in transcription elongation, impacting TCEAL3-related processes. Triptolide and Flavopiridol Hydrochloride disrupt the transcription elongation process by targeting components of the transcription machinery such as the XPB subunit of TFIIH and CDK9. Actinomycin D interferes with RNA synthesis by binding to DNA, which could indirectly affect transcriptional processes involving TCEAL3. I-BET151 and JQ1 inhibit BET bromodomain proteins, impacting transcription regulation at the chromatin level.

Pladienolide B and KPT 330 affect RNA processing and nuclear export, respectively, both crucial in post-transcriptional regulation that could intersect with TCEAL3's function. Rocaglamide and Cordycepin target translation and RNA polyadenylation, influencing gene expression regulation. Lastly, Burixafor, as a CXCR4 antagonist, could have implications on cell signaling pathways, impacting transcription regulation relevant to TCEAL3. These chemicals provide potential avenues to explore the transcriptional and post-transcriptional regulation processes that may be related to TCEAL3's function.